Latest News

Patch testing finds higher prevalence of ACD among children with AD


 

FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Children with atopic dermatitis (AD) were significantly more likely to have positive patch test results than were children without AD, according to a study of over 900 children evaluated for allergic contact dermatitis (ACD) with patch testing, a finding that investigators say underscores the value of considering ACD in patients with AD and referring more children for testing.

ACD is underdetected in children with AD. In some cases, it may be misconstrued to be AD, and patch testing, the gold standard for diagnosing ACD, is often not performed, said senior author JiaDe Yu, MD, MS, a pediatric dermatologist and director of contact and occupational dermatology at Massachusetts General Hospital, Boston, and his co-authors, in the study published in the Journal of the American Academy of Dermatology.

JiaDe Yu, MD, MS, pediatric dermatologist and director of contact and occupational dermatology at Massachusetts General Hospital, Boston Dr. JiaDe Yu

Dr. JiaDe Yu

Dr. Yu and his colleagues utilized a database in which dermatologists and some allergists, all of whom had substantive experience in patch testing and in diagnosing and managing ACD in children, entered information about children who were referred to them for testing.

Of 912 children referred for patch testing between 2018 and 2022 from 14 geographically diverse centers in the United States (615 with AD and 297 without AD), those with AD were more likely to have more than one positive reaction (odds radio, 1.57; 95% confidence interval, 1.14-2.14; P = .005) and had a greater number of positive results overall (2.3 vs. 1.9; P = .012).

AD and ACD both present with red, itchy, eczema-like patches and plaques and can be “really hard to differentiate,” Dr. Yu said in an interview.

“Not everybody with AD needs patch testing,” he said, “but I do think some [patients] who have rashes in unusual locations or rashes that don’t seem to improve within an appropriate amount of time to topical medications ... are the children who probably should have patch testing.”

Candidates for patch testing include children with AD who present with isolated head or neck, hand or foot, or anal or genital dermatitis, Dr. Yu and his colleagues write in the study. In addition, Dr. Yu said in the interview, “if you have a child who has AD that involves the elbow and back of the knees but then they get new-onset facial dermatitis, say, or new-onset eyelid dermatitis ... there’s [significant] value in patch testing.”

Children with AD in the study had a more generalized distribution of dermatitis and were significantly less likely to have dermatitis affecting the anal or genital region, the authors note in the study.

Asked to comment on the results, Jennifer Perryman, MD, a dermatologist at UCHealth, Greeley, Colo., who performs patch testing in children and adults, said that ACD is indeed “often underdiagnosed” in children with AD, and the study “solidifies” the importance of considering ACD in this population.

Jennifer Perryman, MD, dermatologist at UCHealth, Greeley, Colorado UCHealth

Dr. Jennifer Perryman

“Clinicians should think about testing children when AD is [not well controlled or] is getting worse, is in an atypical distribution, or if they are considering systemic treatment,” she said in an e-mail.

“I tell my patients, ‘I know you have AD, but you could also have comorbid ACD, and if we can find and control that, we can make you better without adding more to your routine, medications, etc.’ ” said Dr. Perryman, who was not involved in the research.

Pages

Recommended Reading

Reduction in S aureus skin infections may reduce the risk for eczema herpeticum in atopic dermatitis
MDedge Dermatology
Patients with non-alcoholic fatty liver disease have a lower risk for atopic dermatitis
MDedge Dermatology
No association between dupilumab treatment and risk for arthralgia in atopic dermatitis
MDedge Dermatology
Upadacitinib an effective treatment option in AD patients with recent discontinuation of dupilumab
MDedge Dermatology
CHMP recommends marketing of biologic for atopic dermatitis
MDedge Dermatology
Commentary: Are "significant" results necessarily clinically meaningful? October 2023
MDedge Dermatology
Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Dual Biologic Therapy
MDedge Dermatology
Study finds inflammatory bowel disease risk higher in children, adults with atopic dermatitis
MDedge Dermatology
FDA issues letter regarding lebrikizumab review for atopic dermatitis
MDedge Dermatology
What’s Eating You? Noble False Widow Spider (Steatoda nobilis)
MDedge Dermatology